The company's last update was positive, so why are Polynovo (ASX:PNV) shares still among the most shorted on the ASX?

Short sellers are targeting Polynovo shares…

Key points
  • Polynovo shares up 2.33% yesterday, but down close to 14% for 2022
  • Investors are heavily targeting Polynovo shares with a short interest of 8.89%
  • The company's inconsistent performance is weighing down investor sentiment

The Polynovo Ltd (ASX: PNV) share price has continued to decline despite the company reporting positive numbers in mid-January.

While the medical device company's shares rose 2.33% to $1.315 yesterday, it hasn't been so great in 2022. In fact, for the past 6 weeks (year to date), Polynovo shares have tumbled by almost 14%.

Below, we take a look at what is impacting the company's share price of late.

A small child carrying a brief case tries to reach an elevator button outside closed elevator doors.

Image source: Getty Images

Polynovo shares in top 10 open ASX short positions

The investor sentiment on the Polynovo share price has been negative due to the inconsistent performance of the business. This has ultimately attracted a large number of short sellers to the company's registry.

Short-selling is a common trading strategy that aims to profit from the fall in the price of a security. The goal is for an investor to first borrow and sell the shares, and then buy them back at a lower price for a profit.

Last week, the Australian Securities & Investments Commission (ASIC) released its short position report revealing the level of short interest within companies.

As such, Polynovo remained in the top 10 list with 8.89% of its shares being heavily shorted by investors.

In comparison, the government body had a short interest of 3.65% in Polynovo last year on 4 February.

Given the large increase in short positions being taken up, it appears investors believe the company's performance will be underwhelming.

Polynovo is scheduled to release its FY22 half-year results within the next two weeks.

Polynovo share price snapshot

Over the past 12 months, the Polynovo share price has continued its downward trend to post a 50% loss.

In comparison, the S&P/ASX 200 Healthcare (ASX: XHJ) sector has lost around 5% in the same time frame.

It's worth noting that Polynovo shares hit a multi-year low of $1.185 late last month. This is a huge difference from when its shares were trading above the $4 mark in December 2020.

Polynovo presides a market capitalisation of about $870.12 million and has approximately 661.69 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Expert names 'undervalued' ASX 200 healthcare stock to buy today

A top fundie expects more outperformance from this resurgent ASX healthcare share.

Read more »

A gavel is placed on a stand on a desk with a legal representative wearing a suit in the background.
Healthcare Shares

Cochlear shares fall as investors face another setback

Cochlear shares are back in the red.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the Medibank share price a buy for its 6% dividend yield?

This business is offering very healthy dividends.

Read more »